Physician profile
Arjun Das
NPI 1811170533
$4,524.51
in general payments reported to CMS, 2019-2025
35 companies · $906 in 2025
The $906 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $757 · 2020: $71.70 · 2021: $486 · 2022: $1,044 · 2023: $485 · 2024: $775 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,056 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,056.38 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $602.52 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $513.60 | 2019-2025 | Tavneos, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $435.40 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $373.78 | 2020-2025 | Acthar, Terlivaz |
| Mallinckrodt Enterprises LLC | $355.62 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $291.41 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $206.62 | 2019-2023 | Veltassa |
| Ardelyx, INC. | $195.36 | 2024-2025 | Ibsrela |
| Novartis Pharmaceuticals Corporation | $159.87 | 2020-2025 | |
| Akebia Therapeutics INC | $149.18 | 2021-2025 | Vafseo |
| Calliditas Therapeutics US INC. | $144.80 | 2023-2025 | Tarpeyo |
| Horizon Therapeutics Plc | $129.36 | 2019-2023 | Krystexxa |
| Aurinia Pharma U.S., INC. | $124.61 | 2021-2024 | Lupkynis |
| Opko Pharmaceuticals, LLC | $124.42 | 2019-2024 | Rayaldee |
| Ani Pharmaceuticals, INC. | $81.04 | 2022-2025 | Purified Cortrophin Gel |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $67.03 | 2019 | |
| Janssen Pharmaceuticals, INC | $63.04 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.48 | 2023-2024 | Gattex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.14 | 2023-2024 | Jardiance |
| Travere Therapeutics, INC. | $46.50 | 2021-2025 | Filspari |
| Alexion Pharmaceuticals, INC. | $45.02 | 2021-2022 | |
| Glaxosmithkline, LLC. | $37.28 | 2022-2025 | Benlysta |
| Novo Nordisk INC | $35.00 | 2025 | Ozempic |
| Renalytix Ai, INC. | $34.64 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Apellis Pharmaceuticals, INC. | $32.20 | 2025 | Empaveli |
| Fresenius USA Marketing, INC. | $31.20 | 2022-2025 | Velphoro |
| Scpharmaceuticals INC. | $23.07 | 2024 | |
| La Jolla Pharmaceutical Company | $18.33 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.38 | 2019 | |
| Biomerieux INC | $16.43 | 2023 | |
| Genzyme Corporation | $16.01 | 2025 | |
| Genentech USA, INC. | $13.92 | 2019 | |
| Daiichi Sankyo INC. | $13.09 | 2019 | |
| Lundbeck LLC | $13.00 | 2019 | |
| Baxter Healthcare | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arjun Das listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.